HTB South

Generic dolutegravir-based FDCs at US $75 a year for low- and middle-income countries

Polly Clayden, HIV i-Base 

A new pricing agreement has been announced that will speed up access to generic, dolutegravir-based fixed dose combinations (FDCs). 

This will enable use to treat HIV in low- and middle-income countries (LMICs) at an annual cost per person of around US $75. [1]

Read full report at this link.

Links to other websites are current at date of posting but not maintained.